NYSE: LLY
ELI LILLY & Co Stock

LLY Price
$141.31
Fair Value Price
N/A
Market Cap
$135.16B
52 Week Low
$110.20
52 Week High
$169.13
P/E
22.83x
P/B
33.02x
P/S
6.49x
PEG
1.64x
Dividend Yield
1.96%
Revenue
$22.95B
Earnings
$5.62B
Gross Profit Margin
78.70%
Operating Margin
27.85%
Net Profit Margin
24.50%
Debt to Equity
9.21
Operating Cash Flow
$6B
Beta
0.74
Next Earnings
Oct 27, 2020
Ex-Dividend
Nov 12, 2020
Next Dividend
Dec 10, 2020

Zen Score

High
Medium
Low
51
Industry average

Reasons for this score

LLY ($141.31) is trading below its intrinsic value of $385.70, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
LLY is good value based on its earnings relative to its share price (22.83x), compared to the US market average 38.92x)
Valuation
LLY is good value based on its earnings relative to its share price (22.83x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

1 of 13

LLY News

Valuation

LLY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
22.83x
Industry
-11.07x
Market
38.92x
LLY is good value based on its earnings relative to its share price (22.83x), compared to the US market average 38.92x)
Valuation
LLY is good value based on its earnings relative to its share price (22.83x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

LLY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
33.02x
Industry
7.85x
Market
65.04x
LLY is good value based on its book value relative to its share price (33.02x), compared to the US market average (65.04x)
Valuation
LLY is poor value based on its book value relative to its share price (33.02x), compared to the US Drug Manufacturers - General industry average (7.85x)
Valuation

LLY price to earnings growth (PEG)

For valuing profitable companies with growth potential
LLY is poor value relative to its rate of earnings growth, measured by PEG ratio (1.64x)
Valuation

LLY's financial health

Profit margin

Revenue
$5.9B
Net Income
$1.5B
Profit Margin
24.90%
LLY's Earnings (EBIT) of $6.39B can safely cover interest payments on company debt ($16.33B)
Financials
LLY's profit margin has decreased (-11.70%) in the last year from (36.20%) to (24.50%)
Financials

Assets to liabilities

Assets
$41.1B
Liabilities
$37.9B
Debt to equity
5.60
LLY's short-term assets ($14.58B) exceed its short-term liabilities ($11.99B)
Financials
LLY's long-term liabilities ($25.71B) exceed its short-term assets ($14.58B)
Financials
LLY's debt has increased relative to shareholder equity (9.21), over the past 5 years ago (1.45)
Financials
LLY's debt to equity ratio (9.21) is considered high
Financials

Cash flow

Operating
$382.4M
Investing
-$1.1B
Financing
$106.7M
LLY's operating cash flow ($6.35B) is sufficient to service the company's debt ($16.33B)
Financials

ELI LILLY & Stock FAQ

(NYSE: LLY) ELI LILLY & trades on the NYSE under the ticker symbol LLY. ELI LILLY & stock quotes can also be displayed as NYSE: LLY.
(NYSE: LLY) ELI LILLY & stock price per share is $141.31 today (as of Oct 21, 2020).
(NYSE: LLY) ELI LILLY &'s 52-week high was $169.13, and its 52-week low was $110.20. It is currently -16.45% from its 52-week high and 28.23% from its 52-week low.
(NYSE: LLY) ELI LILLY &'s market cap is $135.16B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

ELI LILLY &'s market cap is calculated by multiplying LLY's current stock price of $141.31 by LLY's total outstanding shares of 956,450,448.
(NYSE: LLY) ELI LILLY & currently has 956,450,448 outstanding shares. With ELI LILLY & stock trading at $141.31 per share, the total value of ELI LILLY & stock (market capitalization) is $135.16B.

ELI LILLY & stock was originally listed at a price of $69.63 in Dec 31, 1997. If you had invested in ELI LILLY & stock at $69.63, your return over the last 22 years would have been 102.94%, for an annualized return of 3.27%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics